Jeffrey B. Locke - Search Results

Year	Number of Results
2006	1
2007	2
2008	2
2009	3
2010	4
2011	3
2012	2
2013	2
2014	5
2015	1
2016	2
2017	1
2018	2
2019	1
2020	1
2021	0

1

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae.

Tóth Z, Forgács L, Locke JB, Kardos G, Nagy F, Kovács R, Szekely A, Borman AM, Majoros L. Tóth Z, et al. Among authors: locke jb. J Antimicrob Chemother. 2019 Dec 1;74(12):3505-3510. doi: 10.1093/jac/dkz390. J Antimicrob Chemother. 2019. PMID: 31539426 Free PMC article.

2

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species.

Tóth Z, Forgács L, Kardos T, Kovács R, Locke JB, Kardos G, Nagy F, Borman AM, Adnan A, Majoros L. Tóth Z, et al. Among authors: locke jb. J Fungi (Basel). 2020 Aug 17;6(3):136. doi: 10.3390/jof6030136. J Fungi (Basel). 2020. PMID: 32824464 Free PMC article.

3

CD101: a novel long-acting echinocandin.

Zhao Y, Perez WB, Jiménez-Ortigosa C, Hough G, Locke JB, Ong V, Bartizal K, Perlin DS. Zhao Y, et al. Among authors: locke jb. Cell Microbiol. 2016 Sep;18(9):1308-16. doi: 10.1111/cmi.12640. Epub 2016 Jul 22. Cell Microbiol. 2016. PMID: 27354115 Free PMC article.

4

Tedizolid for the management of human infections: in vitro characteristics.

Locke JB, Zurenko GE, Shaw KJ, Bartizal K. Locke JB, et al. Clin Infect Dis. 2014 Jan;58 Suppl 1:S35-42. doi: 10.1093/cid/cit616. Clin Infect Dis. 2014. PMID: 24343830 Review.

5

Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species.

Wiederhold NP, Locke JB, Daruwala P, Bartizal K. Wiederhold NP, et al. Among authors: locke jb. J Antimicrob Chemother. 2018 Nov 1;73(11):3063-3067. doi: 10.1093/jac/dky280. J Antimicrob Chemother. 2018. PMID: 30032217

6

Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species.

Locke JB, Almaguer AL, Donatelli JL, Bartizal KF. Locke JB, et al. Infect Dis Obstet Gynecol. 2018 Feb 22;2018:7040498. doi: 10.1155/2018/7040498. eCollection 2018. Infect Dis Obstet Gynecol. 2018. PMID: 29681727 Free PMC article.

7

Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete.

Jang KH, Nam SJ, Locke JB, Kauffman CA, Beatty DS, Paul LA, Fenical W. Jang KH, et al. Among authors: locke jb. Angew Chem Int Ed Engl. 2013 Jul 22;52(30):7822-4. doi: 10.1002/anie.201302749. Epub 2013 Jun 17. Angew Chem Int Ed Engl. 2013. PMID: 23776159 Free PMC article.

8

Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design.

Teng M, Hilgers MT, Cunningham ML, Borchardt A, Locke JB, Abraham S, Haley G, Kwan BP, Hall C, Hough GW, Shaw KJ, Finn J. Teng M, et al. Among authors: locke jb. J Med Chem. 2013 Feb 28;56(4):1748-60. doi: 10.1021/jm301756m. Epub 2013 Feb 12. J Med Chem. 2013. PMID: 23362938

9

Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.

Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, Prokocimer P. Ong V, et al. Among authors: locke jb. Drug Metab Dispos. 2014 Aug;42(8):1275-84. doi: 10.1124/dmd.113.056697. Epub 2014 May 29. Drug Metab Dispos. 2014. PMID: 24875463 Clinical Trial.

10

Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species.

Locke JB, Almaguer AL, Zuill DE, Bartizal K. Locke JB, et al. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6100-7. doi: 10.1128/AAC.00620-16. Print 2016 Oct. Antimicrob Agents Chemother. 2016. PMID: 27480852 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results